...
首页> 外文期刊>Leukemia and lymphoma >Primary mediastinal large B-cell lymphomas treated with dose-intensified CHOP alone or CHOP combined with radiotherapy.
【24h】

Primary mediastinal large B-cell lymphomas treated with dose-intensified CHOP alone or CHOP combined with radiotherapy.

机译:原发性纵隔大B细胞淋巴瘤仅用剂量增强的CHOP或CHOP联合放疗进行治疗。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

We retrospectively reviewed 105 cases of primary mediastinal large B-cell lymphoma (PMLBL). Patients were treated with dose-intensified chemotherapy according to the GELA protocols without planned radiotherapy. Radiotherapy was delivered to patients with a lymphoma proven sensitive to CHOP who could receive irradiation for localised disease. Seventy-six patients achieved a complete remission (24%) or unconfirmed CR (49%), and 15 (14%), a partial remission. Patients treated with intensified induction therapy had a better FFP rate than patients treated with CHOP chemotherapy even when radiotherapy was restricted to partial responders to the dose-intensified chemotherapy regimen (p = 0.01). In the multivariate analysis for overall survival, a poor performance status and CHOP chemotherapy remained associated with a poor outcome (p = 0.02 and 0.02, respectively). Radiotherapy might not be necessary in PMLBL when a CR or a Cru is achieved with dose-intensified chemotherapy. CHOP chemotherapy yield inferior results compared to dose-intensified chemotherapy with more frequent progression on therapy.
机译:我们回顾性回顾了105例原发性纵隔大B细胞淋巴瘤(PMLBL)。根据GELA协议对患者进行了剂量增强化疗,但未计划放疗。放疗已被证明对CHOP敏感的淋巴瘤患者可以接受局部疾病的放射治疗。 76例患者完全缓解(24%)或CR不确定(49%),部分缓解15例(14%)。即使放疗仅限于对剂量强化化疗方案有部分反应者,接受强化诱导治疗的患者的FFP率也高于接受CHOP化疗的患者(p = 0.01)。在总体生存率的多变量分析中,不良的表现状态和CHOP化疗仍与不良的预后相关(分别为p = 0.02和0.02)。当通过剂量强化化学疗法达到CR或Cru时,在PMLBL中可能不需要放疗。与剂量强化化疗相比,CHOP化疗的效果较差,且治疗进展更为频繁。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号